FDA Prior Knowledge Framework for Cell and Gene Therapy: Draft Guidance June 2026

FDA's June 2026 draft guidance on reusing CMC, nonclinical, and clinical prior knowledge to accelerate gene therapy development, and its interaction with the Plausible Mechanism Framework.

FDA's Most Ambitious Effort to Accelerate Gene Therapy

On June 2, 2026, the FDA published a draft guidance titled Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing — the agency's most detailed framework yet for allowing cell and gene therapy (CGT) developers to reuse existing scientific and regulatory knowledge across multiple programs rather than starting from scratch for each new product. The guidance focuses on human gene therapy products incorporating ex vivo and in vivo genome editing of somatic cells, but its principles may also apply to AAV vectors, nanoparticle-based therapies, and ex vivo-modified cell therapies that do not involve gene editing (FDA press release, June 2, 2026; pharmaphorum; RAPS).

The guidance arrives during a period of significant upheaval at the FDA. CBER's acting director Karim Mikhail emphasized that the aim is to "get safe and effective cell and gene therapies to patients faster, particularly those living with rare and life-threatening diseases who have few or no other treatment options." Vijay Kumar, acting director of CBER's Office of Therapeutic Products, added: "Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy" (pharmaphorum; BioSpace).

This analysis explains what the guidance proposes, how it interacts with CBER's other recent initiatives, what it means for gene therapy developers, and what steps sponsors should take during the comment period.

What "Prior Knowledge" Means in This Context

The FDA distinguishes two categories of prior knowledge that sponsors may leverage:

Public Knowledge

Publicly available information from scientific literature, regulatory databases, public master files, and data generated by collaborative efforts between academic institutions, industry, and other stakeholders. This includes published biodistribution studies, established vector characterization methods, and known toxicity profiles for specific capsid serotypes (FDA draft guidance; RAPS).

Platform Knowledge

Proprietary or internal knowledge about a technology that has been licensed, approved, or is in advanced development. Common CGT platforms include:

Viral vector systems — AAV (serotypes 2, 5, 8, 9), lentivirus, adenovirus
Genome editing tools — CRISPR-Cas9, base editors, prime editors, zinc finger nucleases
Delivery technologies — Lipid nanoparticles (LNPs), viral vectors, electroporation
Manufacturing processes — Cell culture, purification, fill-finish methods

A company that has developed an AAV9-based gene therapy for one disease has accumulated extensive platform knowledge about that capsid's manufacturing, quality profile, and biodistribution. A second program using the same capsid could leverage this data rather than generating it from scratch (IntuitionLabs; ASGCT Regulatory Playbook).

Critically, the guidance does not establish a blanket exemption from data generation. Sponsors must provide a scientific rationale demonstrating the applicability of leveraged data to their specific product and development context (PharmExec; FDA draft guidance).

CMC Prior Knowledge: What Can Be Reused

The guidance provides detailed recommendations on leveraging chemistry, manufacturing, and controls (CMC) data across programs:

Analytical Methods

Validated analytical methods from a prior program may be leveraged for a new product using the same platform. This includes method qualification data, validation data, and established acceptance criteria. For example, if a company has validated an empty/full capsid assay for AAV9 vectors, the same method may apply to subsequent AAV9 programs with appropriate justification (RAPS; IntuitionLabs).

Lot Release Specifications

Historical lot release data from a platform product can inform specification setting for subsequent products. Trends in critical quality attributes — potency, vector genome titer, residual host cell DNA — established across multiple batches of a platform product provide a data-driven foundation for new product specifications (FDA draft guidance).

Stability Data

Existing stability studies may support reduced stability testing requirements for new products that share formulation, container closure, and storage conditions with a platform product. This is particularly relevant for AAV programs where real-time stability data at -80°C or -60°C has been generated over multiple years (PharmExec).

Process Characterization and Validation

Manufacturing process data — including process parameters, in-process controls, and validation results — may be leveraged across programs using the same production platform. If a suspension cell culture process for AAV9 production has been validated at commercial scale, a new AAV9 program using the same process may reference this validation package (RAPS; FDA draft guidance).

Manufacturing Facilities

Data from manufacturing facilities previously inspected by FDA and used for platform products may support facility-related sections of new regulatory submissions, reducing the need for duplicative facility documentation (FDA draft guidance; PharmExec).

Comparability Data

When a manufacturing process change is made for a new product, existing comparability data from the platform product may inform the comparability strategy, particularly when the change is analogous to one previously evaluated (RAPS).

Nonclinical Prior Knowledge

For nonclinical data, the extent of leveraging depends on the similarity between the prior product and the new product across several dimensions:

For Ex Vivo Genome Editing Products

Leveraging may depend on:

Similarity in on-target genomic edits
Cell source (autologous vs. allogeneic)
Manufacturing processes for the edited cells
Formulation and delivery methods

For In Vivo Genome Editing Products

Leveraging may depend on:

Similarities and differences in the editing components
Manufacturing processes and final formulations
Route of administration
Proposed clinical dosing regimens and dose levels

The guidance supports a scenario where a company has conducted GLP toxicity studies for one AAV8-based therapy (e.g., a metabolic disease program) and is now developing a different AAV8-based therapy (e.g., an ophthalmic indication). If the route of administration and dose levels are similar, results from the prior toxicity program may serve as nonclinical prior knowledge for the new program (IntuitionLabs; FDA draft guidance).

Clinical Prior Knowledge

The guidance also addresses how clinical data from prior programs may support new development:

Safety databases from related products can inform safety monitoring plans for new programs, particularly for known class effects (e.g., liver enzyme elevations with AAV vectors, cytokine release with CAR-T products).
Dose-response relationships established in prior programs may guide starting dose selection for new products using the same platform.
Biomarker data from related programs may support accelerated clinical development by providing mechanistic evidence of target engagement.

For genome editing therapies, the guidance works in tandem with the FDA's companion draft guidance on Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing (published April 2026), which recommends methods for evaluating off-target editing risks (FDA press release; AABB).

Interaction with the Plausible Mechanism Framework

This draft guidance is one component of a coordinated set of CBER actions in the cell and gene therapy space. It complements the Plausible Mechanism Framework, published as draft guidance on February 23, 2026, which provides a pathway for developing individualized therapies targeting specific genetic conditions with known biological cause (FDA; ASGCT).

The Plausible Mechanism Framework is designed for bespoke, individualized gene therapies — such as the custom CRISPR therapy that treated critically ill baby KJ in 2025. It allows sponsors to rely on a shared mechanistic understanding across patients with the same underlying genetic cause, rather than treating each patient-specific product as an entirely new drug requiring a full development program (FierceBiotech; NEJM).

The prior knowledge guidance provides the scientific tools and data-sharing strategies that make the Plausible Mechanism Framework operationally feasible. Together, the two guidances create a layered approach:

Framework	Target Products	Key Innovation
Plausible Mechanism Framework	Individualized therapies for specific genetic conditions	Shared mechanistic evidence across patients
Prior Knowledge Guidance	Platform-based gene therapies (genome editing)	Reuse of CMC, nonclinical, and clinical data across programs
NGS Safety Assessment Guidance	All genome editing products	Standardized off-target risk evaluation

Together with the CMC Flexibilities guidance (published May 2026), these documents form a comprehensive regulatory toolkit for CGT developers (FDA CBER guidance page; PharmExec).

Practical Implications for Developers

Who Benefits Most

The guidance is particularly impactful for:

Companies with multiple programs using the same platform. A company developing three AAV9-based therapies for different rare diseases can now formally reference a shared CMC and nonclinical data package.
Developers of genome editing therapies. CRISPR, base editing, and prime editing programs can leverage knowledge about the editing tool, delivery vector, and manufacturing process across indications.
Rare disease developers. Small patient populations and limited clinical data are the norm. Prior knowledge reduces the data generation burden, which is disproportionately costly for rare disease programs.

What Does Not Change

The requirement for product-specific safety and efficacy data remains.
Sponsors must still provide a scientific rationale for every piece of leveraged data.
FDA retains full discretion to request additional studies if the relevance of prior data is uncertain.

Early Engagement Is Critical

The guidance strongly encourages early regulatory engagement through INTERACT meetings, pre-IND consultations, and pre-BLA meetings to discuss how prior knowledge will be applied to specific development programs (PharmExec; FDA draft guidance). This is not advisory — it is effectively required, because the applicability of prior knowledge is inherently product-specific and cannot be determined in the abstract.

The Broader Regulatory Context

Gene Therapy at a Crossroads

The guidance arrives amid a paradoxical moment for gene therapy regulation. On one hand, the FDA is actively creating new pathways to accelerate development. On the other, rejection rates for orphan products have climbed sharply — analysts tracking CBER decisions in early 2026 noted rejection rates approaching 30%, compared to approximately 10% in prior years (BioSpace opinion piece, June 2026).

Former FDA Commissioner Marty Makary's departure on May 12, 2026, and the ongoing leadership vacuum at CBER (where acting director Karim Mikhail replaced Vinay Prasad after his departure in March) add institutional uncertainty. Erik Paulsen, chairman of the Institute for Gene Therapies and former Member of Congress, wrote that "predictability at the FDA is not a bureaucratic nicety — it is a lifeline" for the gene therapy community (BioSpace, June 2026).

The prior knowledge guidance can be read as an effort to provide that predictability through a structured, science-based framework — even as leadership transitions continue.

International Implications

The platform-based approach described in the guidance aligns with similar initiatives in other jurisdictions:

The UK MHRA's AI Airlock pilot and evolving regulatory sandbox framework are exploring similar platform-based approaches for advanced therapies.
The EMA's adaptive pathways program and the European Commission's proposed MDR/IVDR amendments include provisions for leveraging existing evidence.
Health Canada and Japan's PMDA have both signaled interest in platform-based regulatory approaches for gene therapies.

What Sponsors Should Do Now

1. Audit Your Platform Knowledge

Identify all CMC, nonclinical, and clinical data generated across your existing programs that could serve as prior knowledge for future products. This includes validated analytical methods, process characterization data, stability studies, GLP toxicology reports, and clinical safety databases.

2. Map Platform Similarities

For each new product in your pipeline, map the specific platform elements shared with prior products — vector type, capsid serotype, route of administration, manufacturing process, formulation. Document the scientific rationale for why prior data is relevant.

3. Request Early Meetings

Engage with FDA through INTERACT or pre-IND meetings to discuss your prior knowledge strategy before filing. The guidance makes clear that early alignment on data leveraging expectations is essential.

4. Submit Comments

The draft guidance is open for public comment for 90 days from Federal Register publication (Docket No. FDA-2026-D-1257). Industry input on practical implementation challenges will be important — particularly on the boundaries of what constitutes sufficient scientific rationale for data leveraging.

5. Prepare Master Files

If your company has platform data that could benefit multiple programs, consider submitting it to FDA through a master file. The guidance explicitly references master files as a source of prior knowledge that can be referenced across multiple INDs and BLAs (pharmaphorum; FDA draft guidance).

Sources

FDA, "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing; Draft Guidance for Industry," June 2, 2026
FDA press release, "FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients," June 2, 2026
Federal Register, Docket No. FDA-2026-D-1257, June 3, 2026
RAPS, "FDA aims to speed gene therapy development with prior scientific knowledge guidance," June 2, 2026
PharmExec, "New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge," June 2026
pharmaphorum, "FDA prior knowledge guide seeks to speed cell, gene therapy," June 3, 2026
AABB, "FDA Releases Draft Guidance on Use of Prior Knowledge in Gene Therapy Development," June 3, 2026
IntuitionLabs, "FDA CGT Guidance 2026: Knowledge Reuse & CMC Submissions," June 2026
ASGCT, "Plausible Mechanism Framework Guidance Document: Comments," April 27, 2026
BioSpace, "Opinion: The next FDA commissioner must be a champion for gene therapies," June 5, 2026
FierceBiotech, "FDA illuminates new approval pathway for bespoke gene therapies," February 2026
FDA CBER, Cellular & Gene Therapy Guidances page (current as of June 2026)